Human Protein Turnover Project (HuPTuP)

Atrium MC Heerlen0 个研究点目标入组 35 人开始时间: 待定最近更新: 2024年6月11日

试验速览

暂无简介。

•Age 18 to 85 years
•- Compos mentis
•- Surgical intervention for oesophagus carcinoma, colon carcinoma, aortic valve insufficiency, lung carcinoma, renal rell carcinoma, epilepsy, hip fracture or osteo-arthritis of the knee
•- Written informed consent

•- Co-morbidities and neuromuscular disorders of the lower limbs severely interacting with mobility with limited or no opportunity for improvement (e.g. cerebral palsy);
•- Peripheral arterial disease Fontaine III or IV;
•- Chronic obstructive pulmonary disease (COPD) GOLD III or IV;
•- Use of systemic steroids in the past four weeks, other than indicated for the specific type of surgery;
•- Use anti-inflammatory biologicals (e.g. TNF-alfa blockers) in the past four weeks;
•- Phenylketonuria (PKU);
•- Surgical intervention in the past four weeks;
•- Insulin dependent diabetes mellitus;
•- Total parenteral nutrition at day of surgery;
•- Pregnancy;
•- Neoadjuvant chemo- or radiotherapy in the past four weeks;
•- Organ-specific exclusion criteria (see below).
•Organ specific exclusion criteria:
•- Medical history of ischemic heart disease
•- Heart failure
•- Diabetes Mellitus
•- GFR < 20 ml/min/1.73 m2
•- Life expectancy <6 months
•- Time to surgery >48 hours
•- Use of injected corticosteroids in the replaced knee the past 3 months
•- Use of bisphosphonates in the past 3 months
•- Rheumatoid arthritis or other inflammatory joint diseases
•- Knee surgery within the last 3 months
•- Osteoarthritis of the knee secondary to septic arthritis, osteonecrosis, fracture, OD and tumor
•- Collagen disorders, e.g. Marfan and Ehler-Danlos

发起方

Atrium MC Heerlen